ILA
Director Trades
| Date | Director | Value |
|---|---|---|
| 24/7/25 | J. Carroll | $21,122 |
Company News
Island Pharmaceuticals Expedites Purchase of Galidesivir RNA Anti-Viral Program
Anti-viral drug development company Island Pharmaceuticals (ASX: ILA) has expedited its US$550,000 acquisition of the galidesivir anti-viral program from US-based BioCryst Pharmaceuticals. The move followed “considerable confidence” that Island gained in the asset from an extensive due diligence process that included a dataset review and collaboration with consultants to define a pathway for regulatory approvals. […]
Island Pharmaceuticals reports positive anti-viral results from Phase 2a of dengue fever trial
Island Pharmaceuticals (ASX: ILA) has announced that lead candidate ISLA-101 has shown positive safety and antiviral activity in a Phase 2a cohort of its PROTECT Phase 2a/b trial into the treatment of dengue fever. The trial is assessing whether the drug can prevent or reduce viremia (a medical condition where viruses enter the bloodstream) and […]
Weekly wrap: rumours of wars send the ASX 200 tumbling
It is the Bible that talks about not being alarmed by “wars and rumours of wars” but Australian share market investors weren’t quite so sanguine, pushing down the ASX 200 sharply. By the close of trade on Friday 55.2 points or 0.7% had been erased from the ASX 200 as the reality of a worsening […]
Island Pharmaceuticals initiates dosing of Phase2a patients in ISLA-101 dengue fever trial
Antiviral drug development company Island Pharmaceuticals (ASX: ILA) has initiated the dosing of all subjects in the Phase 2a component of its ISLA-101 Phase 2a/b PROTECT clinical trial to treat dengue fever. The trial capitalises on years of research by the US Army to develop a live attenuated strain of the dengue virus, which can […]
Island Pharmaceuticals acquires exclusive right to develop antiviral drug galidesivir
Island Pharmaceuticals (ASX: ILA) has signed a deal with US-based BioCryst Pharmaceuticals to take over the development program for antiviral molecule galidesivir. The proposed acquisition aligns with Island’s strategy to address urgent viral disease and medical countermeasure development. Under the terms of a binding agreement, Island will pay BioCryst a US$50,000 option fee for exclusive […]
Island Pharmaceuticals advances dengue fever treatment with promising ISLA-101 study results
Australian antiviral drug development company Island Pharmaceuticals (ASX: ILA) continues to achieve promising results from testing of a potential treatment for the widely-spread dengue fever. The latest assessment of its ISLA-101 drug candidate has returned “highly encouraging” pharmacokinetics (PK) data from a single ascending dose study. The new 24-subject ISLA-101 study has provided critical PK […]